Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Neurim Pharmaceuticals Ltd.
Age
2–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject must be 2 to 17 years old
Subject has a documented history of autistic spectrum disorder (ASD; as confirmed according to, DSM-IV-TR 299.00, 299.10 and 299.80 or ICD 10: F 84.0, F84.2, F84.3, F84.5, F84.9 ) or one of the following neurogenetic diseases according to ICD 10: Smith-Magenis syndrome, Angelman syndrome or Tuberous Sclerosis (Bourneville's disease)
Subject has current sleep problems; defined as difficulty initiating or maintaining sleep, or non restorative sleep, for at least 1 month (DSM-IV 307.42). Subject is able to comply with taking the study drug and collaborate freely with the study procedures;
Written informed consent from parents having parental responsibility or from the legal guardian(s). In the case of a child is aged 12 years or older the written informed consent of the child is needed in addition to that of parents having responsibility/legal guardian;
Subject is able to understand instructions in Dutch.
You may not be if
Subject has history of difficulty with swallowing and/or easy choking;
Subject has current symptoms suggestive of obstructive sleep apnea syndrome or any breathing related sleep disorders or periodic limb movements;
Subject has known clinically significant disturbance(s) in hepatic and/or renal function;
Subject has non-stable epileptic attacks within 3 months prior to screening, in case of a history of epilepsy;
Subject who currently has asthmatic symptoms;
Subject has untreated medical/psychological condition that may be the etiology of sleep disturbances;
Subject is unable to refrain from the use of disallowed concomitant medication ordietary supplements (see paragraph 3.4) from 1 week prior to study occasions;
Subject is unable to refrain from caffeine-containing products for 24 hours before each occasion;
Subject has a known allergy to melatonin;
Female subject who is pregnant at time of screening;
Subject has unstable use of allowed medication within 2 months prior to the screening;
Subject has clinically relevant periodontal disease and/or oral injuries as judged by the investigator;
Subject is unable to refrain from eating bananas and chocolate during the entire day before saliva collection;
Subject is unable to refrain from drinks containing artificial colorants, caffeine (including but not limited to coffee, tea, cola), or alcohol during the day of the collection;
Subject is unable to refrain from aspirin or drugs that contain ibuprofen on the collection day;
Participation in an investigational drug study within 90 days prior to the first dose and/or participation in more than 4 clinical trials in the last year. -